Ospemifene has been authorized for the treatment of vulvovaginal atrophy (VVA). This study wasto evaluate adverse events (AEs) associated with ospemifene by data mining the US Food and Drug Administra
Supplementary data B Any reported adverse event that occurred in less than 5% of any group – grouped under the primary System Organ Class, according to the MedDRA coding system.
